• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2026 Jul;20(7):e70292.
doi: 10.1111/irv.70292.
Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection

Boshu Chen[SUP] 1 [/SUP], José Victor Zambrana[SUP] 1 2 [/SUP], Abigail Shotwell[SUP] 1 [/SUP], Nery Sanchez[SUP] 2 [/SUP], Miguel Plazaola[SUP] 2 [/SUP], Sergio Ojeda[SUP] 2 [/SUP], Roger Lopez[SUP] 2 3 [/SUP], Daniel Stadlbauer[SUP] 4 [/SUP], Guillermina Kuan[SUP] 2 3 [/SUP], Angel Balmaseda[SUP] 2 5 [/SUP], Florian Krammer[SUP] 4 6 7 8 9 [/SUP], Aubree Gordon[SUP] 1 [/SUP]


Affiliations
Abstract

Background: Although the hemagglutination inhibition (HAI) titer remains the gold standard correlate of protection against influenza, it does not fully capture the broader antibody responses that contribute to immunity.
Methods: We analyzed immune responses in paired pre-infection and convalescent sera from 306 RT-PCR-confirmed A(H3N2) infections from two household studies (2014-2018) in Managua, Nicaragua. Antibody responses were measured by HAI and enzyme-linked immunosorbent assays (ELISAs) against full-length hemagglutinin (HA), the HA stalk, and neuraminidase (NA). Participants were classified as HAI responders (≥ 4-fold HAI rise), alternate responders (no HAI rise but ≥ 4-fold boost in ≥ 1 ELISA), or no-response individuals (no ≥ 4-fold rise in any assay). We compared demographic, clinical, and pre-infection antibody characteristics across these groups. We also analyzed predictors of an NA response.
Results: Overall, 77% of participants had HAI seroconversion or a fourfold rise. Among the 23% HAI non-responders, 62% had alternate antibody responses. No-response individuals had the highest pre-infection HAI and full-length HA titers (p < 0.01), the lowest viral loads, and the lowest frequency of fever or influenza-like illness symptoms (p < 0.01). An NA response was more common among symptomatic individuals and moderate baseline titers, with both low and high extremes reducing NA response odds.
Conclusions: High baseline HAI titers can limit detectable fourfold rises and are associated with milder illness. Evaluating additional immune responses may capture a more complete picture of the host response to infection, thereby improving surveillance and informing vaccine development.

Keywords: correlates of protection; hemagglutination inhibition (HAI); influenza A/H3N2; neuraminidase antibodies; symptomatic versus asymptomatic infection.

 
Back
Top